Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2020

Revenue From Contract With Customer [Abstract]

Product and Product-Related Service Revenue from Sale of Instruments and Consumables

Product and Product-related Services Revenue

The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and nine months ended September 30, 2020 and 2019 as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Product revenue:
Instruments	$	71,742	$	414,491	$	563,396	$	1,100,606
Consumables		764,605		1,058,386		2,091,848		2,218,674
Total product revenue		836,347		1,472,877		2,655,244		3,319,280
Product-related services revenue:
Custom RUO assay design		238,502		2,129,251		1,210,968		3,978,428
RUO sample processing		626,219		708,915		1,551,519		4,100,208
Total product-related services revenue		864,721		2,838,166		2,762,487		8,078,636
Total product and product-related services revenue	$	1,701,068	$	4,311,043	$	5,417,731	$	11,397,916

Schedule of Collaborative Development Services

Collaborative Development Services Revenue

The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606, Revenue from Contracts with Customers and ASC 808, Collaborative Arrangements to determine the appropriate recognition of revenue under our collaborative research, development and commercialization agreements that contain multiple elements. For the three and nine months ended September 30, 2020 and 2019, collaborative development services revenue was generated through statements of work entered into under the Governing Agreement with QML as follows:  

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Collaborative development services	$	76,030	$	1,093,750	$	548,135	$	3,006,022

Schedule of Changes in Contract Liability

Changes in the Company’s contract liability were as follows as of the dates indicated:

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2020	$	95,148		$	66,216		$	438,090		$	599,454
Deferral of revenue		335,265			459,385			77,104			871,754
Recognition of deferred revenue		(325,181	)		(525,601	)		(95,670	)		(946,452	)
Balance at September 30, 2020	$	105,232		$	—		$	419,524		$	524,756

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2019	$	116,547		$	50,000		$	244,400		$	410,947
Deferral of revenue		126,425			671,885			463,814			1,262,124
Recognition of deferred revenue		(172,610	)		(707,641	)		(229,192	)		(1,109,443	)
Balance at September 30, 2019	$	70,362		$	14,244		$	479,022		$	563,628